Related Experiment Video

Updated: Aug 19, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Current state of pneumococcal vaccines

T Wuorimaa1, H Käyhty

  • 1Department of Vaccines, National Public Health Institute, Helsinki, Finland.

Scandinavian Journal of Immunology
|July 18, 2002
PubMed

Insights

Streptococcus pneumoniae causes millions of childhood deaths annually. This review examines current and developing vaccines, highlighting the need for broader serotype coverage and infant efficacy in pneumococcal vaccines.

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Streptococcus pneumoniae is a major global cause of childhood pneumonia and meningitis.
  • Pneumococcal pneumonia causes over a million deaths in children under five annually.
  • Emerging antibiotic resistance necessitates novel vaccine strategies.

Purpose of the Study:

  • To review the current landscape of pneumococcal diseases and vaccines.
  • To assess the limitations of existing vaccines, particularly in infants and low-resource settings.
  • To highlight the development of new conjugate vaccines with expanded serotype coverage.

Main Methods:

  • Literature review of existing pneumococcal vaccines.
  • Analysis of serotype prevalence and vaccine efficacy data.
  • Evaluation of ongoing clinical trials for novel pneumococcal vaccines.

Main Results:

  • The 23-valent polysaccharide vaccine is effective in adults but not infants.
  • The 7-valent conjugate vaccine shows infant efficacy but limited serotype coverage globally.
  • Several 11-valent conjugate vaccines are in development, aiming for broader coverage and improved infant immunogenicity.

Conclusions:

  • There is a critical need for cost-effective pneumococcal vaccines with extensive serotype coverage for all age groups.
  • Conjugate vaccines are essential for inducing immunological memory in infants.
  • Ongoing development of 11-valent vaccines shows promise in addressing global pneumococcal disease burden.

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...